Bioisosterism: A Rational Approach in Drug Design.
暂无分享,去创建一个
[1] Y. Martin,et al. A practitioner's perspective of the role of quantitative structure-activity analysis in medicinal chemistry. , 1981, Journal of medicinal chemistry.
[2] G. Flynn. Substituent Constants for Correlation Analysis in Chemistry and Biology. , 1980 .
[4] Rodney L. Johnson,et al. Synthesis and dopamine receptor modulating activity of lactam conformationally constrained analogues of Pro-Leu-Gly-NH2. , 1993, Journal of medicinal chemistry.
[5] A J Hopfinger,et al. Three-dimensional molecular shape analysis-quantitative structure-activity relationship of a series of cholecystokinin-A receptor antagonists. , 1994, Journal of medicinal chemistry.
[6] W. Gould,et al. Sulfonanilides. II. Analogs of Catecholamines. , 1967, Journal of medicinal chemistry.
[7] U. Kristiansen,et al. Electrophysiological studies of the GABAA receptor ligand, 4‐PIOL, on cultured hippocampal neurones , 1991, British journal of pharmacology.
[8] B. Peskar. On the synthesis of prostaglandins by human gastric mucosa and its modification by drugs. , 1977, Biochimica et biophysica acta.
[9] D. Sliskovic,et al. Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents. , 1991, Trends in pharmacological sciences.
[10] G. Tsukamoto,et al. Organic Phosphorus Compounds. Part 2. Synthesis and Coronary Vasodilator Activity of (Benzothiazolylbenzyl)phosphonate Derivatives. , 1989 .
[11] J. Kraus,et al. Isosterism and molecular modification in drug design: tetrazole analogue of GABA: effects on enzymes of the gamma-aminobutyrate system. , 1983, Pharmacological research communications.
[12] Y. Hashimoto,et al. New type inducers of differentiation of human HL-60 promyelocytic leukemia cells. Terephthalic anilides. , 1984, Chemical & pharmaceutical bulletin.
[13] C. Yen,et al. 3,3-Diphenyl-3-(2-alkyl-1,3,4-oxadiazol-5-yl)propylcycloalkylamines, a novel series of antidiarrheal agents. , 1976, Journal of medicinal chemistry.
[14] T. T. Chou,et al. Benzyloxazolidine-2,4-diones as potent hypoglycemic agents. , 1991, Journal of medicinal chemistry.
[15] P. Kelbaugh,et al. Rotationally restricted mimics of rigid molecules: nonspirocyclic hydantoin aldose reductase inhibitors. , 1989, Journal of medicinal chemistry.
[16] T. Uno,et al. Synthesis of antimicrobial agents. 3. Syntheses and antibacterial activities of 7-(4-hydroxypiperazin-1-yl)quinolones. , 1990, Journal of medicinal chemistry.
[17] H. J. Hess,et al. Synthesis and biological activity of carboxyl-terminus modified prostaglandin analogues. , 1979, Journal of medicinal chemistry.
[18] Y. Hashimoto,et al. Retinobenzoic acids. 2. Structure-activity relationships of chalcone-4-carboxylic acids and flavone-4'-carboxylic acids. , 1989, Journal of medicinal chemistry.
[19] M. Tominaga,et al. Novel thiazole derivatives as inhibitors of superoxide production by human neutrophils: synthesis and structure-activity relationships. , 1995, Journal of medicinal chemistry.
[20] R. Stanfield,et al. Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 2. Modification of fatty acid anilide ACAT inhibitors: bioisosteric replacement of the amide bond. , 1993, Journal of medicinal chemistry.
[21] T. Rimele,et al. Indole-phenol bioisosterism. Synthesis and antihypertensive activity of a pyrrolo analogue of labetalol. , 1986, Journal of medicinal chemistry.
[22] Q. Sun,et al. Synthesis and evaluation of terbenzimidazoles as topoisomerase I inhibitors. , 1995, Journal of medicinal chemistry.
[23] R. Ball,et al. Tryptophan-derived NK1 antagonists: conformationally constrained heterocyclic bioisosteres of the ester linkage. , 1995, Journal of medicinal chemistry.
[24] J. Wessale,et al. Nonpeptide renin inhibitors with good intraduodenal bioavailability and efficacy in dog. , 1994, Journal of medicinal chemistry.
[25] G. Tsukamoto,et al. Organic phosphorus compounds. 2. Synthesis and coronary vasodilator activity of (benzothiazolylbenzyl) phosphonate derivatives. , 1989, Journal of medicinal chemistry.
[26] L. Iversen,et al. A novel series of non‐quaternary oxadiazoles acting as full agonists at muscarinic receptors , 1990, British journal of pharmacology.
[27] A. Lapucci,et al. An interdisciplinary approach to the design of new structures active at the beta-adrenergic receptor. Aliphatic oxime ether derivatives. , 1985, Journal of medicinal chemistry.
[28] M. Chlenov,et al. Synthesis of indane derivatives as mechanism-based inhibitors of dopamine β-hydroxylase , 1995 .
[29] G. Stankus,et al. Characterization of the Cardiotonic Effects of Milrinone, a New and Potent Cardiac Bipyridine, on Isolated Tissues from Several Animal Species , 1983, Journal of cardiovascular pharmacology.
[30] P. Seeman,et al. The conformation of dopamine at its receptor: binding of monohydroxy-2-aminotetralin enantiomers and positional isomers. , 1979, Molecular Pharmacology.
[31] R. Robinson,et al. Œstrogenic Activity of Certain Synthetic Compounds , 1938, Nature.
[32] S. Freedman,et al. Synthesis and biological activity of 1,2,4-oxadiazole derivatives: highly potent and efficacious agonists for cortical muscarinic receptors. , 1990, Journal of medicinal chemistry.
[33] R. Ferone,et al. Benzoquinazoline inhibitors of thymidylate synthase: enzyme inhibitory activity and cytotoxicity of some 3-amino- and 3-methylbenzo[f]quinazolin-1(2H)-ones. , 1993, Journal of medicinal chemistry.
[34] F. Bymaster,et al. Novel Functional M1 Selective Muscarinic Agonists. Synthesis and Structure→Activity Relationships of 3‐(1,2,5‐Thiadiazolyl)‐1,2,5,6‐tetrahydro‐1‐methylpyridines. , 1992 .
[35] R. K. Mishra,et al. Dopamine receptor modulation by conformationally constrained analogues of Pro-Leu-Gly-NH2. , 1988, Journal of medicinal chemistry.
[36] James E. Huheey,et al. The Electronegativity of Groups , 1965 .
[37] L. Goodman,et al. The Pharmacological Basis of Therapeutics , 1941 .
[38] R. Lum,et al. Synthesis and antiviral activity of a novel class of HIV-1 protease inhibitors containing a heterocyclic P1′-P2′ amide bond isostere , 1994 .
[39] P. Bonnet,et al. Modulation of leukocyte genetic expression by novel purine nucleoside analogues. A new approach to antitumor and antiviral agents. , 1993, Journal of medicinal chemistry.
[40] D. Hoekman. Exploring QSAR Fundamentals and Applications in Chemistry and Biology, Volume 1. Hydrophobic, Electronic and Steric Constants, Volume 2 J. Am. Chem. Soc. 1995, 117, 9782 , 1996 .
[41] Y. Hashimoto,et al. Differentiation inducers of human promyelocytic leukemia cells HL-60. Phenylcarbamoylbenzoic acids and polyene amides. , 1986, Chemical & pharmaceutical bulletin.
[42] W. Jackson,et al. Benzophenone dicarboxylic acid antagonists of leukotriene B4. 2. Structure-activity relationships of the lipophilic side chain. , 1990, Journal of medicinal chemistry.
[43] L. Whitby. CHEMOTHERAPY OF BACTERIAL INFECTIONS , 1938 .
[44] G. Mckenzie,et al. Synthesis and dopaminergic activity of (+/-)-, (+)-, and (-)-2-dipropylamino-5-hydroxy-1,2,3,4-tetrahydronaphthalene. , 1976, Journal of medicinal chemistry.
[45] T. Honoré,et al. Muscarinic cholinergic agonists and antagonists of the 3-(3-alkyl-1,2,4-oxadiazol-5-yl)-1,2,5,6-tetrahydropyridine type. Synthesis and structure-activity relationships. , 1991, Journal of medicinal chemistry.
[46] B. Kim,et al. A new peptide bond surrogate: 2-isoxazoline in pseudodipeptide chemistry , 1992 .
[47] R. Crossley,et al. Synthesis and antiinflammatory activity of certain 5,6,7,8-tetrahydroquinolines and related compounds. , 1995, Journal of medicinal chemistry.
[48] Heikkila Re,et al. Pharmacological basis of therapeutics: dopamine receptors. , 1984 .
[49] A. Black,et al. Leukotriene B4‐like material in scale of psoriatic skin lesions , 1984, British journal of pharmacology.
[50] R. Gillespie,et al. 2-(Oxadiazolyl)- and 2-(Thiazolyl)imidazo(1,2-a)pyrimidines as Agonists and Inverse Agonists at Benzodiazepine Receptors. , 1991 .
[51] B. Baker. Some Analogs of Hexestrol , 1943 .
[52] A Burger,et al. Isosterism and bioisosterism in drug design. , 1991, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.
[53] C. Thornber,et al. Isosterism and molecular modification in drug design , 1979 .
[54] C. Martini,et al. Conformationally restrained β-blocking oxime ethers: synthesis and β-adrenergic properties of diastereoisomeric anti and syn 2-(5′-isoxazolidinyl)-ethanolamines , 1992 .
[55] D. R. Curtis,et al. Synthesis and biological activity of a GABAA agonist which has no effect on benzodiazepine binding and of structurally related glycine antagonists. , 1987, Drug design and delivery.
[56] P. Krogsgaard‐Larsen,et al. GABA agonists and potential antagonists related to muscimol , 1979, Brain Research.
[57] T. Himi,et al. Retinobenzoic acids. 4. Conformation of aromatic amides with retinoidal activity. Importance of trans-amide structure for the activity. , 1989, Journal of medicinal chemistry.
[58] P. Kelleher,et al. Insulin-dependent? , 1985, The Lancet.
[59] G. Cristalli,et al. Synthesis and antitumor activity of 2-beta-D-ribofuranosyloxazole-4-carboxamide (oxazofurin). , 1990, Journal of medicinal chemistry.
[60] S. Ross. IN VIVO INACTIVATION OF CATECHOLAMINES IN MICE. , 2009, Acta pharmacologica et toxicologica.
[61] Raymond C. F. Jones,et al. Amide bond isosteres: Imidazolines in pseudopeptide chemistry , 1988 .
[62] C. Swain,et al. Identification of L-tryptophan derivatives with potent and selective antagonist activity at the NK1 receptor. , 1994, Journal of medicinal chemistry.
[63] K. Suckling,et al. Role of acyl-CoA: cholesterol acyltransferase in cellular cholesterol metabolism. , 1985, Journal of lipid research.
[64] R. Mishra,et al. Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindings , 1981, Peptides.
[65] S. O’Rahilly,et al. Pathogenesis of NIDDM--a disease of deficient insulin secretion. , 1988, Bailliere's clinical endocrinology and metabolism.
[66] D. R. Curtis,et al. DIHYDROMUSCIMOL, THIOMUSCIMOL AND RELATED HETEROCYCLIC COMPOUNDS AS GABA ANALOGUES , 1979, Journal of neurochemistry.
[67] M. Fournié-Zaluski,et al. New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension. , 1994, Journal of medicinal chemistry.
[68] F E Blaney,et al. Comparison of azabicyclic esters and oxadiazoles as ligands for the muscarinic receptor. , 1991, Journal of medicinal chemistry.
[69] M. Dolan,et al. 8-Substituted O6-benzylguanine, substituted 6(4)-(benzyloxy)pyrimidine, and related derivatives as inactivators of human O6-alkylguanine-DNA alkyltransferase. , 1995, Journal of medicinal chemistry.
[70] M. Kuhar,et al. 3-Aryl-2-(3'-substituted-1',2',4'-oxadiazol-5'-yl)tropane analogues of cocaine: affinities at the cocaine binding site at the dopamine, serotonin, and norepinephrine transporters. , 1993, Journal of medicinal chemistry.
[71] P. Calabresi,et al. Potentiation of 5-fluoro-2'-deoxyuridine antineoplastic activity by the uridine phosphorylase inhibitors benzylacyclouridine and benzyloxybenzylacyclouridine. , 1984, Cancer research.
[72] M. Peterson,et al. Spiro hydantoin aldose reductase inhibitors. , 1988, Journal of medicinal chemistry.
[73] M. E. Goldberg. Pharmacological and biochemical properties of drug substances , 1977 .
[74] G. Lepage,et al. BIOCHEMICAL AND CARCINOSTATIC EFFECTS OF 2'-DEOXYTHIOGUANOSINE. , 1964, Cancer research.
[75] Corwin Hansch,et al. The physicochemical approach to drug design and discovery (QSAR) , 1981 .
[76] L. Waterbury,et al. Synthesis and pharmacological evaluation of N,N-di-n-propyldopamine congeners containing phenolic bioisosteres. , 1987, Journal of pharmaceutical sciences.
[77] M. Peterson,et al. Sorbinil: a member of the novel class of spirohydantoin aldose reductase inhibitors. , 1986, Metabolism: clinical and experimental.
[78] F. Labrie,et al. Synthesis and in vitro evaluation of 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17 beta-carboxamides as 5 alpha-reductase inhibitors and antiandrogens. , 1995, Journal of medicinal chemistry.
[79] Christopher A. Lipinski,et al. Chapter 27. Bioisosterism in Drug Design , 1986 .
[80] R. Olsen,et al. GABAA receptor channels. , 1994, Annual review of neuroscience.
[81] D. R. Curtis,et al. STRUCTURE AND BIOLOGICAL ACTIVITY OF A SERIES OF CONFORMATIONALLY RESTRICTED ANALOGUES OF GABA , 1975, Journal of neurochemistry.
[82] N. Ackerman,et al. Synthesis and antiinflammatory and analgesic activity of 5-aroyl-6-(methylthio)-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-ca rboxyl ic acids and 1-methyl-4-(methylthio)-5-aroylpyrrole-2-acetic acids. , 1989, Journal of medicinal chemistry.
[83] F. Muggia. Concepts, Clinical Developments, and Therapeutic Advances in Cancer Chemotherapy , 2011, Cancer treatment and research.
[84] Baldev Singh,et al. Synthesis of analogs of amrinone: 4-(3,4-Disubstitutedphenyl)pyridines and derivatives thereof , 1991 .
[85] W. Brouillette,et al. 3-Amino-5,5-dimethylhexanoic acid. Synthesis, resolution, and effects on carnitine acyltransferases. , 1994, Journal of medicinal chemistry.
[86] C. Braestrup,et al. Oxadiazoles as bioisosteric transformations of carboxylic functionalities. II , 1996 .
[87] G. Metcalf,et al. Drug Design via Pharmacophore Identification. Dopaminergic Activity of 3H- Benz[e]indol-8-amines and Their Mode of Interaction with the Dopamine Receptor. , 1986 .
[88] W. Dallas,et al. Catalytic role of histidine 147 in Escherichia coli thymidylate synthase. , 1989, The Journal of biological chemistry.
[89] A. Schousboe,et al. GABAA receptor agonists, partial agonists, and antagonists. Design and therapeutic prospects. , 1994, Journal of medicinal chemistry.
[90] D. Baccanari,et al. Inhibition of uridine phosphorylase: synthesis and structure-activity relationships of aryl-substituted 5-benzyluracils and 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils. , 1995, Journal of medicinal chemistry.
[91] J. Kemp,et al. Second-generation benzodiazepine CCK-B antagonists. Development of subnanomolar analogs with selectivity and water solubility. , 1994, Journal of medicinal chemistry.
[92] W. Stenson,et al. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. , 1984, Gastroenterology.
[93] Ruth E. McDermott,et al. Novel thiazolidine-2,4-diones as potent euglycemic agents. , 1992, Journal of medicinal chemistry.
[94] K. Bogeso,et al. Bioisosteres of arecoline: 1,2,3,6-tetrahydro-5-pyridyl-substituted and 3-piperidyl-substituted derivatives of tetrazoles and 1,2,3-triazoles. Synthesis and muscarinic activity. , 1994, Journal of medicinal chemistry.
[95] Y. Hashimoto,et al. Chalcone carboxylic acids. Potent differentiation inducers of human promyelocytic cells HL-60. , 1985, Chemical & pharmaceutical bulletin.
[96] R. DeFronzo. The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM , 1988, Diabetes.
[97] J. Metzger,et al. Synthesis and biological evaluation of NK1 antagonists derived from L-tryptophan. , 1995, Journal of medicinal chemistry.
[98] L. Field,et al. Steric effects. A study of a rationally designed system , 1980 .
[99] R. D. Dyer,et al. Synthesis and Biological Evaluation of 5-((3,5-Bis(1,1-dimethylethyl)- 4-hydroxyphenyl)methylene)oxazoles, -thiazoles, and -imidazoles: Novel Dual 5-Lipoxygenase and Cyclooxygenase Inhibitors with Antiinflammatory Activity. , 1994 .
[100] Y. Hashimoto,et al. Retinobenzoic acids. 5. Retinoidal activities of compounds having a trimethylsilyl or trimethylgermyl group(s) in human promyelocytic leukemia cells HL-60. , 1990, Journal of medicinal chemistry.
[101] D. Dunn,et al. Analysis of pilocarpine and isopilocarpine in ophthalmic solutions by normal-phase high-performance liquid chromatography. , 1981, Journal of pharmaceutical sciences.
[102] A. Martinelli,et al. Molecular orbital studies on the mechanism of drug-receptor interaction. 2. beta-Adrenergic drugs. An approach to explain the role of the aromatic moiety. , 1977, Journal of medicinal chemistry.
[103] E. De Clercq,et al. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. , 1995, Journal of medicinal chemistry.
[104] J. Sredy,et al. Orally active aldose reductase inhibitors derived from bioisosteric substitutions on tolrestat. , 1989, Journal of medicinal chemistry.
[105] G. Rajakumar,et al. Dopamine receptor modulation by Pro-Leu-Gly-NH2 analogues possessing cyclic amino acid residues at the C-terminal position. , 1986, Journal of medicinal chemistry.
[106] P. Krogsgaard‐Larsen,et al. Heterocyclic analogues of GABA: chemistry, molecular pharmacology and therapeutic aspects. , 1985, Progress in medicinal chemistry.
[107] J. Golden,et al. THE PRIMARY SITE OF INHIBITION BY 6-MERCAPTOPURINE ON THE PURINE BIOSYNTHETIC PATHWAY IN SOME TUMORS IN VIVO. , 1963, Cancer Research.
[108] F. Naguib,et al. Differences in activities and substrate specificity of human and murine pyrimidine nucleoside phosphorylases: implications for chemotherapy with 5-fluoropyrimidines. , 1993, Cancer research.
[109] E. Corey,et al. Structure of leukotriene C. Identification of the amino acid part. , 1979, Biochemical and biophysical research communications.
[110] H. Brown,et al. The Structure and Toxicity of DDT Insecticides , 1953 .
[111] R. K. Mishra,et al. Interaction of l‐Prolyl‐l‐Leucyl Glycinamide with Dopamine D2 Receptor: Evidence for Modulation of Agonist Affinity States in Bovine Striatal Membranes , 1988, Journal of neurochemistry.
[112] M. Forest,et al. A novel class of cardiotonic agents: synthesis and biological evaluation of 5-substituted 3,6-dihydrothiadiazin-2-ones with cyclic AMP phosphodiesterase inhibiting and myofibrillar calcium sensitizing properties. , 1992, Journal of medicinal chemistry.
[113] D. R. Curtis,et al. A new class of GABA agonist , 1977, Nature.
[114] R. J. Bontems,et al. Bicyclic thiazolidine lactam peptidomimetics of the dopamine receptor modulating peptide Pro-Leu-Gly-NH2. , 1993, Journal of medicinal chemistry.
[115] M. Raiteri,et al. Multiple GABAB receptors. , 1993, Trends in pharmacological sciences.
[116] L. Thibault,et al. A bio-assay for the concomitant assessment of the antiphlogistic and thymolytic activities of topically applied corticoids. , 1965, Endocrinology.
[117] P. Krogsgaard‐Larsen,et al. Recent Advances in GABA Agonists, Antagonists and Uptake Inhibitors: Structure–Activity Relationships and Therapeutic Potential , 1988 .
[118] S. Moreland,et al. Dihydropyrimidine calcium channel blockers. 2. 3-substituted-4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic acid esters as potent mimics of dihydropyridines. , 1990, Journal of medicinal chemistry.
[119] In vivo characterisation of novel efficacious muscarinic receptor agonists. , 1990, European journal of pharmacology.
[120] A. Larsen,et al. A New Bio-isostere : Alkylsulphonamidophenethanolamines , 1964, Nature.
[121] R. Krell,et al. A novel series of selective leukotriene antagonists: exploration and optimization of the acidic region in 1,6-disubstituted indoles and indazoles. , 1990, Journal of medicinal chemistry.
[122] Thomas Kolter,et al. Peptidomimetics for Receptor Ligands. Discovery, Development, and Medical Perspectives , 1993 .
[123] Thomas Kolter,et al. Peptidomimetics for Receptor Ligands—Discovery, Development, and Medical Perspectives , 1993 .
[124] A. Maycock,et al. Inhibition of human leukocyte elastase. 3. Synthesis and activity of 3'-substituted cephalosporins. , 1990, Journal of medicinal chemistry.
[125] E Falch,et al. A novel class of conformationally restricted heterocyclic muscarinic agonists. , 1986, Journal of medicinal chemistry.
[126] S E Ealick,et al. Structure-based design of inhibitors of purine nucleoside phosphorylase. , 1995, Acta crystallographica. Section D, Biological crystallography.
[127] A. Treasurywala,et al. Novel inhibitors of the nuclear factor of activated T cells (NFAT)-mediated transcription of beta-galactosidase: potential immunosuppressive and antiinflammatory agents. , 1995, Journal of Medicinal Chemistry.
[128] D. Roberts. An isotopic assay for thymidylate synthetase. , 1966, Biochemistry.
[129] Gabriele Cruciani,et al. Principal Properties for Aromatic Substituents. A Multivariate Approach for Design in QSAR , 1989 .
[130] A. Black,et al. The release of leukotriene B4-like material in biologically active amounts from the lesional skin of patients with psoriasis. , 1984, The Journal of investigative dermatology.
[131] J. Vane,et al. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.
[132] J. L. Howard,et al. Benzodiazepine receptor binding activity of 6,9-disubstituted purines. , 1989, Journal of medicinal chemistry.
[133] C. Kaiser,et al. Adrenergic agents. 1. Synthesis and potential beta-adrenergic agonist activity of some catecholamine analogs bearing a substituted amino functionality in the meta position. , 1974, Journal of medicinal chemistry.
[134] I. Langmuir. ISOMORPHISM, ISOSTERISM AND COVALENCE. , 1919 .
[135] J. Mond,et al. 8-Hydroxyguanosine and 8-methoxyguanosine possess immunostimulating activity for B lymphocytes. , 1985, Cellular immunology.
[136] U. Kristiansen,et al. Partial GABAA receptor agonists. Synthesis and in vitro pharmacology of a series of nonannulated analogs of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol. , 1995, Journal of medicinal chemistry.
[137] M. Kimmey. NSAID, ulcers, and prostaglandins. , 1992, The Journal of rheumatology. Supplement.
[138] Y. Hashimoto,et al. Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity. , 1988, Journal of medicinal chemistry.
[139] H. Takahashi,et al. Inhibition of two copper-containing enzymes, tyrosinase and dopamine beta-hydroxylase, by L-mimosine. , 1977, Molecular pharmacology.
[140] A. Lapucci,et al. Molecular design, synthesis, and antiinflammatory activity of a series of beta-aminoxypropionic acids. , 1990, Journal of medicinal chemistry.
[141] D. A. Walsh,et al. Synthesis and antiallergy activity of 4-(diarylhydroxymethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds. , 1989, Journal of medicinal chemistry.